Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam
Status:
Recruiting
Trial end date:
2022-08-04
Target enrollment:
Participant gender:
Summary
Remimazolam is a ultra-short-acting benzodiazepine, and unlike conventional benzodiazepine
drugs, it is rapidly metabolized in plasma and not accumulates in the body for long periods
of infusion or even with high dose administration. In addition, it has no injection pain and
infusion syndrome compared with propofol. In particular, there is no study to investigate
overall postoperative functional recovery via QoR-15 in patients receiving TIVA using
remimazolam. Therefore, rhe purpose of the study is to compare poetoperative quality of
recovery (QoR)-15 scores according to the use of anesthetics for total intravenous anesthesia
in the cervical spine surgery with intraoperative neurophysiological monitoring.